Cumulative Irritation Potential and Contact Sensitization Potential of Tazarotene Foam 0.1% in 2 Phase 1 Patch StudiesBERG, Jeffrey E; BOWMAN, James P; ALIO SAENZ, Alessandra B et al.Cutis (New York, NY). 2012, Vol 90, Num 4, pp 206-211, issn 0011-4162, 6 p.Article

Tazarotene: A New Generation of Receptor-Selective Retinoids. SymposiumJournal of the American Academy of Dermatology. 1997, Vol 37, Num 2, issn 0190-9622, 42 p., 3Conference Proceedings

Impurities of tazarotene : Isolation and structural characterisationBRENNA, Elisabetta; FRIGOLI, Samuele; FRONZA, Giovanni et al.Journal of pharmaceutical and biomedical analysis. 2008, Vol 46, Num 3, pp 574-576, issn 0731-7085, 3 p.Article

Pharmacokinetics and safety review of tazarotene. DiscussionMARKS, R; HORN; YOUNG et al.Journal of the American Academy of Dermatology. 1998, Vol 39, Num 4, pp S134-S138, issn 0190-9622, 2Conference Paper

Optimising the use of tazarotene in clinical practice : Consensus statement from the European Advisory Panel for tazarotene (Zorac⁾GOLLNICK, H. P. M; FINZI, A. F; MARKS, R et al.Dermatology (Basel). 1999, Vol 199, Num 1, pp 40-46, issn 1018-8665Conference Paper

A pilot study to determine the effect of tazarotene gel 0.1% on steroid-induced epidermal atrophyKAIDBEY, Kays; KOPPER, Scott C; SEFTON, John et al.International journal of dermatology. 2001, Vol 40, Num 7, pp 468-471, issn 0011-9059Article

Phototoxic and Photoallergic Potential of Tazarotene Foam 0.1% in 2 Phase 1 Patch StudiesHOGAN, Daniel J; ALIO SAENZ, Alessandra B.Cutis (New York, NY). 2012, Vol 90, Num 5, pp 266-271, issn 0011-4162, 6 p.Article

Confluent and Reticulate Papillomatosis Treated With Minocycline and TazaroteneTSENG, Hui-Wen; TSENG, Hui-Hwa; WU, Chieh-Shan et al.Cutis (New York, NY). 2013, Vol 91, Num 4, pp 194-197, issn 0011-4162, 4 p.Article

Topical tazarotene vs. coal tar in stable plaque psoriasisKUMAR, U; KAUR, I; DOGRA, S et al.Clinical and experimental dermatology (Print). 2010, Vol 35, Num 5, pp 482-486, issn 0307-6938, 5 p.Article

Lamellar ichthyosis treated with tazarotene 0.1% gelKUNDU, Roopal V; GARG, Amit; WOROBEC, Sophie M et al.Journal of the American Academy of Dermatology. 2006, Vol 55, Num 5, issn 0190-9622, S94-S95, SUPArticle

Once-daily tazarotene gel versus twice-daily fluocinonide cream in the treatment of plaque psoriasisLEBWOHL, M; AST, E; QUELL, J. M et al.Journal of the American Academy of Dermatology. 1998, Vol 38, Num 5, pp 705-711, issn 0190-9622, 1Article

Rational design of receptor-selective retinoids. DiscussionCHANDRARATNA, R. A. S; MARKS; MORAHAN et al.Journal of the American Academy of Dermatology. 1998, Vol 39, Num 4, pp S124-S128, issn 0190-9622, 2Conference Paper

Tolerability comparison of adapalene gel, 0.3% versus tazarotene cream, 0.05% in subjects with healthy skin : AcneDOSIK, Jonathan S; ARSONNAUD, Stephanie.Journal of drugs in dermatology. 2007, Vol 6, Num 6, pp 632-638, issn 1545-9616, 7 p.Article

Le médicament du mois : Tazarotène 0,05 %-0,1 % (Zorac®) = Tazarotene 0.05 %-1.1 % (Zorac®)HENNO, A; HUA, M.-T; DE LA BRASSINNE, M et al.RMLG. Revue médicale de Liège. 2003, Vol 58, Num 11, pp 706-708, issn 0370-629X, 3 p.Article

Tazarotene: a new topical retinoid for plaque psoriasisMARKS, R.British journal of dermatology. Supplement. 1999, Vol 140, Num 54, issn 0366-077X, 30 p.Conference Proceedings

Psoriasis : une nouvelle stratégie thérapeutique. ReportageLes Nouvelles dermatologiques. 1999, Vol 18, Num 6, pp 402-405, issn 0752-5370Conference Proceedings

Treatment of ichthyosiform diseases with topically applied tazarotene : Risk of systemic absorptionNGUYEN, Victoria; CUNNINGHAM, Bari B; EICHENFIELD, Lawrence F et al.Journal of the American Academy of Dermatology. 2007, Vol 57, Num 5, issn 0190-9622, S123-S125, SUPArticle

Childhood nail psoriasis: A useful treatment with tazarotene 0.05%DILUVIO, Laura; CAMPIONE, Elena; PATERNO, Evelin J et al.Pediatric dermatology. 2007, Vol 24, Num 3, pp 332-333, issn 0736-8046, 2 p.Article

Tazarotene plus UVB phototherapy in the treatment of psoriasisKOO, John Y. M; LOWE, Nicholas J; LEW-KAYA, Deborah A et al.Journal of the American Academy of Dermatology. 2000, Vol 43, Num 5, pp 821-828, issn 0190-9622Article

Tazarotene-induced gene 2 (TIG2), a novel retinoid-responsive gene in skinNAGPAL, S; PATEL, S; JACOBE, H et al.Journal of investigative dermatology. 1997, Vol 109, Num 1, pp 91-95, issn 0022-202XArticle

Tazarotene: The first receptor-selective topical retinoid for the treatment of psoriasisCHANDRARATNA, R. A. S.Journal of the American Academy of Dermatology. 1997, Vol 37, Num 2, pp S12-S17, issn 0190-9622, 3Conference Paper

Efficacy and Safety Study of Tazarotene Cream 0.1% for the Treatment of Brittle Nail SyndromeSHERBER, Noëlle S; HOCH, Ariel M; COPPOLA, Carol A et al.Cutis (New York, NY). 2011, Vol 87, Num 2, pp 96-103, issn 0011-4162, 8 p.Article

Pharmacokinetics and safety of tazaroteneMENTER, A.Journal of the American Academy of Dermatology. 2000, Vol 43, Num 2, pp 31-35, issn 0190-9622, 3Conference Paper

Clindamycin Phosphate 1.2%―Benzoyl Peroxide (5% or 2.5%) Plus Tazarotene Cream 0.1% for the Treatment of AcneDHAWAN, Sunil S; GWAZDAUSKAS, Jennifer.Cutis (New York, NY). 2013, Vol 91, Num 2, pp 99-104, issn 0011-4162, 6 p.Article

Comparison of tazarotene 0.1 0el plus petrolatum once daily versus calcipotriol 0.0050intment twice daily in the treatment of plaque psoriasisTZUNG, Tien-Yi; WU, Jen-Chin; HSU, Nei-Jen et al.Acta dermato-venereologica. 2005, Vol 85, Num 3, pp 236-239, issn 0001-5555, 4 p.Article